

Application No.: 10/758,672
Amendment and Response Dated May 8, 2006
Reply to a Non-Final Office Action Mailed November 10, 2005

Docket No.: 01017/35966B

AMENDMENT TO THE DRAWINGS

The attached 23 sheets of drawings (**Appendix A**) are formal versions of the informal drawings submitted at the time of filing for Figures 1-12.

REMARKS

I. Preliminary Remarks Regarding Amendments

By the foregoing, the Applicants have amended the specification to Figures 1A-1L for original Figure 1. Also submitted herewith is one set (23 sheets, Figures 1-12) of formal drawings for filing in the above-identified patent application. Kindly substitute the enclosed formal drawings for the informal drawings submitted with the originally filed application. Although the drawings were indicated to be acceptable by the Examiner in this Office Action, the Applicants are submitting revised drawings, in conformity with the prosecution in parent application, U.S. Serial No. 09/724,126, now U.S. Patent No. 6,706,505, issued March 16, 2004.

Claims 9, 12-14, 16-18, 40-45, 49, 50, and 58 are currently pending and claims 13, 14, 16-18, 40-45, 49, and 50 are under examination. Claim 13 has been allowed. Claims 9, 12, and 58 have been withdrawn from consideration for assertedly being drawn to a non-elected invention, but are currently amended to be consistent in format with claims under examination. Claims 14, 16, 17, 40, 43, and 49 are amended herein. Claims 14, 16-18, 40-45, 49, and 50 were rejected under 35 U.S.C. §102(b) and §112, first paragraph (written description and enablement).

Claims 9, 12, 14, 16, and 17 have been amended to replace the abbreviated term “huE3 α ” with the unabbreviated term “human E3 α ubiquitin ligase.” Support for this amendment is found throughout the specification, including at page 1, lines 9-10.

Claim 14 has been amended to recite an isolated polypeptide comprising the amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 2, wherein the encoded polypeptide has human E3 α ubiquitin ligase activity of the polypeptide set forth in SEQ ID NO: 2, thus providing structural and functional characteristics sufficient to identify members of the claimed genus. Support in the specification for a human E3 α ubiquitin ligase polypeptide that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 2 is found at least at page 11, lines 9-15. Support in the specification for human E3 α ubiquitin ligase activity is found at least at page 2, line 8 through page 4, line 14. The specification describes how E3 α ubiquitin ligase functions in the proteosomal pathway.

Claim 16 has been amended to recite an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2 with modifications of one to 100 amino acids

consisting of amino acid substitutions, amino acid insertions, amino acid deletions, and C- and/or N- terminal truncations up to about 100 amino acids, wherein the polypeptide has human E3 α ubiquitin ligase activity of the polypeptide set forth in SEQ ID NO: 2, thus providing structural and functional characteristics sufficient to identify members of the claimed genus. Support in the specification for variants of human E3 α ubiquitin ligase polypeptide with modifications of from one to 100 amino acids is found at page 17, lines 14-32. Support in the specification for human E3 α ubiquitin ligase activity is found at page 2, line 8 through page 4, line 14.

Claim 17 has been amended to recite the stringent conditions necessary for hybridization, along with polypeptide activity, thus providing structural and functional characteristics sufficient to identify members of the claimed genus. Support in the specification for the recited hybridization conditions is found at page 14, line 27, through page 16, line 20. Support in the specification for human E3 α ubiquitin ligase activity is found at page 2, line 8 through page 4, line 14. Claim 17 has also been amended to recite that the nucleotide sequence of subpart (c) hybridizes under expressly recited highly stringent conditions to the complement of the coding sequence of (a) or (b). Claim 17 has been further amended to recite that the nucleotide sequence of subpart (d) is fully complementary any of (a)-(c). Support in the specification for "fully complementary" sequences is found at page 11, lines 27-31.

Claims 40, 43, 49, and 58 have been amended to depend on claims 13, 14, 16, or 17. Claim 43 has been amended to recite "a chemically modified derivative of the polypeptide of claim 13, 14, 16, or 17. Claim 44 has been amended to depend on the polypeptide derivative of claim 43. Support for these amendments is found in the original claims and in the specification at page 24, line 1, through page 25, line 23.

No new matter is introduced by the substitute figures, the references thereto added to the amended specification, or the amended claims. Support for the amendments is found throughout the specification and the original claims as filed.

The Applicants do not intend, with these or any other amendments, to abandon the subject matter of claims previously presented, and reserve the right to pursue such subject matter in duly filed continuing patent applications.

II. Patentability Remarks

A. The Rejection under 35 U.S.C. §102(b) May Properly Be Withdrawn.

The Patent Office rejected all pending claims under 35 U.S.C. § 102(b) as assertedly being anticipated by Kwon et al., *Proc. Natl. Acad. Sci. U.S.A.* 95:7898-7903, 1998 (cited in the Applicants' Information Disclosure Statement); hereinafter "Kwon." Office Action at page 10. Kwon apparently discloses the mouse ortholog of human ubiquitin ligase E3 α polypeptide, which assertedly consists of 1757 amino acids and is 93.4% identical to SEQ ID NO: 2. Based on that characterization, the Examiner asserted that the DNA which encodes the protein thereof will hybridize to SEQ ID NO: 1 under highly stringent conditions. In response, the Applicants disagree.

To invalidate a claim for "anticipation" under 35 U.S.C. § 102, a single reference must identify each and every feature recited in the claim sought to be invalidated. *Scripps Clinic and Research Foundation v. Genentech, Inc.*, 927 F.2d 1565, 1576 (Fed. Cir. 1991).

The Applicants submit that Kwon does not disclose each and every feature recited in the pending claims. Contrary to the Examiner's assertion that Kwon teaches the mouse ortholog of SEQ ID NO: 2 that is 93.4% identical to SEQ ID NO: 2 (*see* page 10 of the Office Action), the polypeptide sequence disclosed by Kwon appears to share at most 92% identity to the polypeptide of SEQ ID NO: 2 (see alignment set forth in **Appendix B**; as aligned using the online BLAST program provided by the National Center for Biotechnology Information at <http://www.ncbi.nlm.nih.gov/blast/bl2seq>). Thus, the Applicants submit that the claims, as amended, exclude the subject matter described by Kwon. For example, the murine UBR1 polypeptide of Kwon fails to anticipate a polypeptide having 95% identity to the amino acid sequence of SEQ ID NO: 2, as recited in claim 14. The murine UBR1 polypeptide of Kwon, which assertedly shares 1619/1757 (92%) amino acid identity with SEQ ID NO: 2 (*see Appendix B*), also fails to anticipate the subject matter of claim 16, which discloses human E3 α ubiquitin ligase variants of SEQ ID NO: 2 with up to 100 amino acid modifications comprising substitutions, insertions, deletions, C-terminal truncations, and/or N-terminal truncations. Moreover, Kwon's mouse ubiquitin ligase E3 α polynucleotide sequence will not hybridize to SEQ ID NO: 1 under the highly stringent conditions recited in claim 17.

Thus, Kwon fails to disclose, expressly or inherently, each limitation of any one of the rejected claims. Accordingly, Kwon fails to anticipate the subject matter of any of the rejected claims. For these reasons, the rejection of claims 14, 16-18, 40-45, 49, and 50 under 35 U.S.C. § 102(b) has been overcome and should be withdrawn.

B. The Rejections Under 35 U.S.C. 112, First Paragraph, May Properly Be Withdrawn.

1. Written Description

The Patent Office rejected claims 14, 16-18, 40, 41, 43-45, 49, and 50 under 35 U.S.C. § 112, first paragraph, for allegedly lacking adequate written description. Office Action at pages 4-6. The Examiner has asserted the following reasons for rejection: 1) claim 14 (b) recites "an ortholog of SEQ ID NO: 2 and claim 14 (c) [apparently the Examiner meant to recite 14 (e)] recites an allelic or splice variant of either the amino acid sequence as set forth in SEQ ID NO: 2, or at least one of (a)-(c), and the Applicants have described only one member of the claimed genus and has not described how the structure of SEQ ID NO: 1 relates to the structure of other allelic or splice variants; 2) claim 16 lacks limitations on the number of modifications that can be made to the polypeptides having the amino acid sequence of SEQ ID NO: 2 with at least one conservative substitution, insertion, deletion, truncation, or a combination of the above and, therefore, fails to provide a sufficient description of the claimed genus in structure and function to identify members of the genus; and 3) the specification fails to provide any structure: function correlation present in all members of the claimed genus.

The Examiner also relied on *University of California v. Eli Lilly and Co.*, 1997 U.S. App. LEXIS 18221, at *23, quoting *Fiers v. Revel*, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993) whereby a claimed genus must (1) fully describe at least one species whereby one of skill, in view of the prior art, could predict the structure of other species encompassed by the claimed genus, and (2) identify the common characteristics of the claimed molecules. The Examiner provided reasons for rejecting independent claims 14 and 16, but did not provide a reason for rejecting independent claim 17 or dependent claims 18, 40, 41, 43-45, 49, and 50 for lack of written description. Office Action at page 6. The Applicants respectfully traverse this rejection

and submit that the claimed subject matter, as originally filed, is adequately described in the specification.

To satisfy the written description requirement under 35 U.S.C. §112, first paragraph, the application as filed must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. *Vas-Cath, Inc. v. Mahurkar*, 19 USPQ.2d 1111 (Fed. Cir. 1991); *see also* M.P.E.P. §2163 (I). Moreover, the initial burden of establishing a *prima facie* case of lack of written descriptive support is on the Office. M.P.E.P. §2163 (II). The Applicants submit that the Patent Office has not met this burden. Moreover, the basis alleged for this rejection is now moot in consideration of the amendments to the claims.

To expedite prosecution, the Applicants have 1) amended claim 14 to remove reference to orthologs and allelic or splice variants and to recite the specific polypeptide activity as being “human E3 α ligase activity”; 2) amended claim 16 to include a limitation on the number of modifications that can be made to the polypeptide having the amino acid sequence of SEQ ID NO: 2 and to recite the specific polypeptide activity as being “human E3 α ligase activity”; and 3) amended claim 17 to include the specific hybridization conditions necessary defining members of the claimed genus and to recite the specific polypeptide activity as being “human E3 α ligase activity.” These amendments provide structural and functional attributions to define members of the claimed genus, thereby overcoming the bases for rejection.

Specifically, claim 14 has been amended to recite an isolated polypeptide comprising an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 2, wherein the encoded polypeptide has human E3 α ubiquitin ligase activity of the polypeptide set forth in SEQ ID NO: 2, thus providing structural and functional characteristics sufficient to identify members of the claimed genus. Support in the specification for human E3 α ubiquitin ligase activity is found at page 2, line 8, through page 4, line 14, wherein the specification describes how E3 α ubiquitin ligase functions in the proteosomal pathway. Also, contrary to the Examiner’s assertion that the Applicants have only provided one allele within the scope of the claimed genus (SEQ ID NO: 2 encoded by SEQ ID NO: 1) (*see* Office Action at page 4), the Applicants note that the specification teaches an allelic variant of SEQ ID NO: 1, namely SEQ ID NO: 18, with a single nucleotide polymorphism (SNP) that

encodes a polypeptide variant of SEQ ID NO: 2 (SEQ ID NO: 19) (*see* Example 9, page 97, line 23 through page 98, line 12). Thus, the specification provides written descriptive support for two alleles of human E3 α ligase within the scope of the claimed genus: two polynucleotides (SEQ ID NOS: 1 and 2) which encode two polypeptides (SEQ ID NOS: 18 and 19, respectively). The claims require that these and other allelic variants possess substantial sequence identity which defines the genus. Further, Figure 1 provides an alignment of the amino acid sequences for human and murine E3 α ubiquitin ligases I and II and, thus, identifies regions of the polypeptides that are highly conserved. Further, conservative amino acid substitutions in polypeptides and the redundancy of the genetic code are well known facts in the art that are effectively described by reciting "variants". Taken together, one of skill in the art would recognize that the Applicants were in possession of the claimed genus.

Claim 16 has been amended to recite a nucleotide sequence encoding a polypeptide set forth in SEQ ID NO: 2 with modifications of one to 100 amino acids consisting of amino acid substitutions, amino acid insertions, amino acid deletions, C-terminal truncation, and/or N-terminal truncation, wherein the polypeptide has human E3 α ubiquitin ligase activity of the polypeptide set forth in SEQ ID NO: 2, thus providing structural and functional characteristics sufficient to identify members of the claimed genus.

The rejection of claim 17, although not specifically supported by rejection for a lack of written description in the Office Action, has been amended to recite the stringent conditions necessary for hybridization and to recite the polypeptide activity (human E3 α ubiquitin ligase activity), thus providing structural and functional characteristics sufficient to identify members of the claimed genus.

In summary, the Applicants submit that amended claims 14, 16, and 17 are described sufficiently by one of skill to reasonably conclude that the inventors were in possession of the claimed genera as of the relevant filing date. Consequently, the rejections under 35 U.S.C. § 112, first paragraph, for lack of written description have been overcome-in-part and are rendered moot-in-part by the amendments to the claims. Moreover, the rejection as it pertains to claims 17, 18, 40, 41, 43-45, 49, and 50 should be withdrawn for failure to establish a *prima facie* basis or any basis, for rejection under 35 U.S.C. § 112, first paragraph, for lack of written description.

2. Enablement

Claims 14, 16-18, 40-45, 49, and 50 were rejected under 35 U.S.C § 112, first paragraph, for assertedly not providing enablement for the broad scope of claims which encompass polypeptides having an amino acid sequence at least 70, 80, 85, 90, or 95% identical to the amino acid sequence of SEQ ID NO: 2 or having no known percent identity to SEQ ID NO: 2 and retaining E3 α ubiquitin ligase activity. The Examiner also rejected the claims for encompassing polypeptides having no defined activity or having E3 α ubiquitin ligase activity that is encoded by a nucleotide sequence that hybridizes under highly stringent conditions to SEQ ID NO: 1. The Examiner then recited the Wands factors (*see In re Wands*, 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir. 1988)) as factors to be considered in determining whether undue experimentation is required. Office Action at pages 6-8. The Applicants respectfully traverse this rejection and submit that the claims, as originally filed, are fully enabled by the specification.

The enablement requirement of 35 U.S.C. § 112, first paragraph, ensures that an application teaches how to make and use the invention as claimed without requiring undue experimentation. The inquiry may be guided by consideration of several factors enumerated in a biotechnology context in *In re Wands*.

The Applicants have amended claims 14, 16, and 17 by defining the claimed sequences with a combination of structural and/or functional characteristics taught in the specification. For example, the variants of claim 14 all possess a recited sequence relationship to SEQ ID NO: 2, namely "at least 95 percent identical to the amino acid sequence of SEQ ID NO: 2, wherein the polypeptide has human E3 α ligase activity of the polypeptide set forth in SEQ ID NO: 2." The application also teaches one how to make and use such variants without undue experimentation (*see* the specification at page 27, line 29, through page 33). The application describes methods of determining identity and similarity, and teaches methods of making conservative and non-conservative amino acid modification. For example, the application explains how conservative modifications to the amino acid sequence (and the corresponding modifications to the encoding nucleotides) will produce human E3 α ubiquitin ligase polypeptides having functional and chemical characteristics similar to those of naturally occurring human E3 α ubiquitin ligase polypeptides.

The Applicants have also amended claim 16 to recite an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2 with modifications of one to 100 amino acids consisting of amino acid substitutions, amino acid insertions, amino acid deletions, C-terminal truncations, and/or N-terminal truncations up to about 100 amino acids, wherein the polypeptide has human E3 α ubiquitin ligase activity of the polypeptide set forth in SEQ ID NO: 2, thus providing structural and functional characteristics sufficient to identify members of the claimed genus. Support in the specification for variants of human E3 α ubiquitin ligase polypeptide with modifications of from one to 100 amino acids is found at page 17, lines 14-32. The specification teaches that variants may be naturally occurring or artificially constructed. The specification also teaches that such variants may be prepared from the corresponding nucleic acid molecules encoding them. Likewise, support in the specification for human E3 α ubiquitin ligase activity is found at page 2, line 8, through page 4, line 14, wherein the specification describes how E3 α ubiquitin ligase functions in the proteosomal pathway.

Claim 17 has been amended to recite the stringent conditions necessary for hybridization and to define the type of polypeptide activity (human E3 α ubiquitin ligase activity) exhibited by the claimed genus of polypeptides, thus providing structural and functional characteristics sufficient to identify members of the claimed genus. The specification teaches various stringent hybridization conditions and provides references for carrying out experiments involving hybridization (*see* page 14, line 27, through page 16, line 20).

Given the base sequence information (e.g., SEQ ID NO: 2), the specifically identified activity of the molecules (*i.e.*, human E3 α ubiquitin ligase activity), and the well-known techniques for detecting such activity, the Applicants submit that one skilled in the art would be able to identify and make the claimed variants of the native human E3 α ubiquitin ligase using no more than routine experimentation.

In view of the foregoing comments and the amendments to the claims, the Applicants submit that claims 14, 16-18, 40-45, 49, and 50 are fully enabled by the present specification and the rejection of the claims under 35 U.S.C. § 112, first paragraph, should be withdrawn.

C. The Rejections Under 35 U.S.C. § 112, Second Paragraph, May Properly Be Withdrawn.

Claims 14, 16-18, 40-45, 49, and 50 were rejected under 35 U.S.C § 112, second paragraph, as assertedly being indefinite for failing to particularly point out and distinctly claim the subject matter that the Applicants regard as their invention. Specifically, the claims were rejected for assertedly: 1) not defining the metes and bounds of the clause “the mature amino acid sequence as set forth in SEQ ID NO: 2 comprising a mature amino terminus at residue 1, optionally further comprising an amino terminal methionine” in claim 14(a) because SEQ ID NO: 2 already contains a methionine at position 1 and claim 42 recites “the mature amino acid sequence as set forth in SEQ ID NO: 2;” 2) reciting “the polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 2” in claims 14 and 16 without defining the activity; 3) reciting “highly stringent conditions” in claim 17 and defining these conditions by non-limiting examples rendering the metes and bounds of claim 17 unascertainable (pages 14-16 of the specification); 4) not defining the degree of complementarity in claim 17(d); 5) being redundant when reciting “the coding sequence” in claim 17(c) because SEQ ID NO: 1 comprises both coding sequence and its complement; and 6) lacking clarity in claim 44 because it is not clear as to which of the two polypeptides recited in base claim 43 is covalently modified by a water-soluble polymer, and because the term “derivative” is defined by non-limiting examples. In response, the Applicants respectfully traverse this rejection. Moreover, this rejection for indefiniteness is now moot in consideration of the amendments to the claims.

Claim 14 has been amended to delete the asserted indefinite subpart 14(a). Claims 14, 16, and 17 have been amended to recite a specific activity for the polypeptide set forth in SEQ ID NO: 2, *i.e.*, “E3 α ligase activity.” Claim 17 has been amended to provide specific conditions required for stringent hybridization. Claim 17 has been amended to recite that the nucleotide sequence of part (d) should be fully complementary to any of (a)-(c). Claim 17 has been amended to state that a nucleotide sequence of 17(c) should hybridize under highly stringent conditions to the complement of the coding sequence of parts (a) or (b). Last, claim 43 has been amended to recite “chemically modified derivative” and claim 44 has been amended to depend on the polypeptide derivative of claim 43. The amendments to claims 14, 16, 17, 43, and 44 have rendered moot the rejections under 35 U.S.C. § 112, second paragraph, as applied to these claims. Dependent claims incorporate the limitations of the base claims from which they

depend. Accordingly dependent claims 18, 40-42, 45, 49, and 50 have been clarified by the clarifying amendments to claims 14, 16, 17, 43, and 44.


In view of the foregoing comments and the amendments herein, the rejection of claims 14, 16-18, 40-45, 49, and 50 under 35 U.S.C. § 112, second paragraph, should be withdrawn.

III. Conclusion

In view of the amendments and remarks provided herein, the Applicants submit that the claims are in condition for allowance and early notification thereof is respectfully requested. Should the Examiner wish to discuss any aspect of the present application, she is urged to contact the undersigned at the telephone number provided below.

Dated: May 8, 2006

Respectfully submitted,

By 

Lynn L. Janulis

Registration No.: 53,066

Agent for Applicants

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300



Blast 2 Sequences results

PubMed

Entrez

BLAST

OMIM

Taxonomy


Structure

BLAST 2 SEQUENCES RESULTS VERSION BLASTP 2.2.12 [Aug-07-2005]

Matrix **BLOSUM62** gap open: **11** gap extension: **1**
x_dropoff: **50** expect: **10000.0** wordsize: **3** Filter ☐ **Align**

Sequence 1 lcl|seq_1 Length 1757 (1 .. 1757)

Sequence 2 lcl|seq_2 Length 1749 (1 .. 1749)



NOTE: Bitscore and expect value are calculated based on the size of the nr database.

Score = 3321 bits (8610), Expect = 0.0

Identities = 1619/1757 (92%), Positives = 1683/1757 (95%), Gaps = 8/1757 (0%)

```
Query: 1   MADEEMDGAERMDVSPEPPLAPQRPASWWDQQVDFYTAFLHHLAQLVPEIYFAEMDPDLE 60
          MADEE G ERM++S E P PQR ASWWDQQVDFYTAFLHHLAQLVPEIYFAEMDPDLE
Sbjct: 1   MADEEAGGTERMEISAE LPQTPQRLASWWDQQVDFYTAFLHHLAQLVPEIYFAEMDPDLE 60

Query: 61  KQEE SVQMSILTPLEWYLFGE D PDICLEKLKHS GAFQLCGK VFKSGETTYSCRDCAIDPT 120
          KQEE SVQMSI TPLEWYLFGE D PDICLEKLKHS GAFQLCG+VFKSGETTYSCRDCAIDPT
Sbjct: 61  KQEE SVQMSIFTPLEWYLFGE D PDICLEKLKHS GAFQLCGRVFKSGETTYSCRDCAIDPT 120

Query: 121 CVLCMDCFQSSVHKNHRYKMHTSTGGGFCDCGDTEAWKTGPFCVDHEPGRAGTTKESLHC 180
          CVLCMDCFQ SVHKNHRYKMHTSTGGGFCDCGDTEAWKTGPFCV+HEPGRAGT KE+ C
Sbjct: 121 CVLCMDCFQDSVHKNHRYKMHTSTGGGFCDCGDTEAWKTGPFCVNHEPGRAGTIKENSRC 180

Query: 181 PLNEEVIAQARRIFPSVIKYIVEMTIWEEEEKELPPELQIREKNERY YCVLFNDEHHSYDH 240
          PLNEEVI QAR+IFPSVIKY+VEMTIWEEEEKELPPELQIREKNERY YCVLFNDEHHSYDH
Sbjct: 181 PLNEEVIVQARKIFPSVIKYVEMTIWEEEEKELPPELQIREKNERY YCVLFNDEHHSYDH 240

Query: 241 VIISLQRALDCELAEAQLHTTAIDKEGRRRAVKAGVYATCQEAKEDIKSHSENV SQHPLHV 300
          VIISLQRALDCELAEAQLHTTAIDKEGRRRAVKAG YA CQEAKEDIKSHSENV SQHPLHV
Sbjct: 241 VIISLQRALDCELAEAQLHTTAIDKEGRRRAVKAGAYAACQEAKEDIKSHSENV SQHPLHV 300

Query: 301 EVLHSVVM AHQKFALRLG SWMNKIMSYSSDFRQIFCQACLVEEPGSEN PCLISRLMLWDA 360
          EVLHS +MAHQKFALRLG SWMNKIMSYSSDFRQIFCQACL EEP SEN PCLISRLMLWDA
Sbjct: 301 EVLHSEIMAHQKFALRLG SWMNKIMSYSSDFRQIFCQACL REEPDSEN PCLISRLMLWDA 360

Query: 361 KLYKGARKILHELIFSSFFMEMEYKKLFAMEFVKYKQLQKEYISDDHERSISITALSVQ 420
          KLYKGARKILHELIFSSFFMEMEYKKLFAMEFVKYKQLQKEYISDDH+RSISITALSVQ
```

Sbjct: 361 KLYKGARKILHELIFSSFFMEMEYKFLFAMEFVKYKQLQKEYISDDHDSISITALSVQ 420

Query: 421 MLTVPTLARHLIEEQNVISVITETLLEVLPEYLDNRNNKFNFGYSQDKLGRVYAVICDLK 480
M TVPTLARHLIEEQNVISVITETLLEVLPEYLDNRNNKFNFGYSQDKLGRVYAVICDLK

Sbjct: 421 MFTVPTLARHLIEEQNVISVITETLLEVLPEYLDNRNNKFNFGYSQDKLGRVYAVICDLK 480

Query: 481 YILISKPVWTERLRAQFLEGFRSFLKILTCMQGMEEIRRQVGQHIEVDPDWEAAIAIQM 540
YILISKP IWTERLR QFLEGFRSFLKILTCMQGMEEIRRQVGQHIEVDPDWEAAIAIQM

Sbjct: 481 YILISKPTIWTERLRMQFLEGFRSFLKILTCMQGMEEIRRQVGQHIEVDPDWEAAIAIQM 540

Query: 541 QLKNILLMFQEWACACDEDELLLVAYKECHKAVMRCSTNFMSSSTKTVVQLCGHSLETYSYKV 600
QLKNILLMFQEWACACDE+LLLVAYKECHKAVMRCST+F+SS+KTVVQ CGHSLETYSY+V

Sbjct: 541 QLKNILLMFQEWACACDEELLLLVAYKECHKAVMRCSTSFISSTKTVVQSCGHSLETYSYRV 600

Query: 601 SEDLVSIHLPLSRTLGLHVRLSRLGAISRLHEFVPFDSFQVEVLVEYPLRCLVLVAQVV 660
SEDLVSIHLPLSRTLGLHVRLSRLGA+SRLHEFV F+ FQVEVLVEYPLRCLVLVAQVV

Sbjct: 601 SEDLVSIHLPLSRTLGLHVRLSRLGAISRLHEFVSFEDFQVEVLVEYPLRCLVLVAQVV 660

Query: 661 AEMWRRNGLSLISQVFYYQDVKCREEMYDKDIIMLQIGASIMDPNKFLLLVLQRYELTDA 720
AEMWRRNGLSLISQVFYYQDVKCREEMYDKDIIMLQIGAS+MDPNKFLLLVLQRYEL +A

Sbjct: 661 AEMWRRNGLSLISQVFYYQDVKCREEMYDKDIIMLQIGASLMDPNKFLLLVLQRYELAEA 720

Query: 721 FNKTISTKDQDLIKQYNTLIEEMLQVLIYIVGERYVPGVGNVTREEVIMREITHLLCIEP 780
FNKTISTKDQDLIKQYNTLIEEMLQVLIYIVGERYVPGVGNVT+EEV MREI HLLCIEP

Sbjct: 721 FNKTISTKDQDLIKQYNTLIEEMLQVLIYIVGERYVPGVGNVTKEEVTMREIIHLLCIEP 780

Query: 781 MPHSAIARNLPENENNETGLENVINKVATFKKPGVSGHGVYELKDESLKDFNMYFYHYSK 840
MPHSAIA+NLPENENNETGLENVINKVATFKKPGVSGHGVYELKDESLKDFNMYFYHYSK

Sbjct: 781 MPHSAIAKNLPENENNETGLENVINKVATFKKPGVSGHGVYELKDESLKDFNMYFYHYSK 840

Query: 841 TQHSKAEHMQKKRRKQENKDEALPPPPPPPEFCPAFSKVNNLLSCDVMYIILRTIFERAVID 900
TQHSKAEHMQKKRRKQENKDEALPPPPPPPEFCPAFSKV+NLL+CD+M+YILRT+FERA+D

Sbjct: 841 TQHSKAEHMQKKRRKQENKDEALPPPPPPPEFCPAFSKVINLLNCDIMMYIILRTVFERAID 900

Query: 901 TESNLWTEGMLQMAFHILALGLEEKQQLQKAPEEEVAFDFYHKASRLGSSAMNAQNIQM 960
T+SNLWTEGMLQMAFHILALGLEEKQQLQKAPEEEV FDFYHKASRLGSSAM NIQM

Sbjct: 901 TDSNLWTEGMLQMAFHILALGLEEKQQLQKAPEEEVTFDFYHKASRLGSSAM---NIQM 957

Query: 961 LLERLKGIPQLEGQKDMITWILQMFDTVRLREKSCLVATTSGLECIKSEEITHDKEKA 1020
LLE+LKGIPQLEGQKDMITWILQMFDTVRLREKSCL+VATTSG E IK++EITHDKEKA

Sbjct: 958 LLEKLKGIPQLEGQKDMITWILQMFDTVRLREKSCLIVATTSGSESIKNDIETHDKEKA 1017

Query: 1021 ERKRKAEAAARLHRQKIMAQMSALQKNFIETHKLMYDNTSEVTGKEDSIMEEESTSAVSEA 1080
ERKRKAEAAARLHRQKIMAQMSALQKNFIETHKLMYDNTSE+ GKEDSIMEEEST AVS+

Sbjct: 1018 ERKRKAEAAARLHRQKIMAQMSALQKNFIETHKLMYDNTSEMPGKEDSIMEEESTPAVSDY 1077

Query: 1081 SRIALGPKRGPVTEKEVLTCLCQEEQEVKLENNAMVLSACVQKSTALTQHRGKPVDDL 1140
SRIALGPKRGP+VTEKEVLTCLCQEEQEVK+ENAMVLSACVQKSTALTQHRGKPV++

Sbjct: 1078 SRIALGPKRGPVTEKEVLTCLCQEEQEVKIENAMVLSACVQKSTALTQHRGKPIELS 1137

Query: 1141 GETLDPLFMDPDLAGHTYTGSCGHVMHAVCWQKYFEAVQLSSQRIHVDLFDLESGEYLC 1200
GE LDPLFMDPDLA+GTYTGSCGHVMHAVCWQKYFEAVQLSSQRIHVDLFDLESGEYLC

Sbjct: 1138 GEALDPLFMDPDLAGHTYTGSCGHVMHAVCWQKYFEAVQLSSQRIHVDLFDLESGEYLC 1197

Query: 1201 PLCKSLCNTVPIIPLQPQKINSENAEALQLLTLARWIQTVLARISGYNIKHAKEAPA 1260
PLCKSLCNTVPIIPLQPQKINSENA+ALQLLTLARWIQTVLARISGYNI+HAKGE P

Sbjct: 1198 PLCKSLCNTVPIIPLQPQKINSENAALQLLTLARWIQTVLARISGYNIRHAKGENP- 1256

Query: 1261 VPVLFNQGMGDSTFEFHSILSFGVQSSVKYSNSIKEMVILFATTIYRIGLKVPPDELDPR 1320
+P+ FNQGMGDST EFHSILSFGV+SS+KYSNSIKEMVILFATTIYRIGLKVPPDE DPR

Sbjct: 1257 IPIFFNQMGDSTLEFHSILSFGVESSIKYSNSIKEMVILFATTIYRIGLKVPPDERDPR 1316

Query: 1321 VPMMTWSTCAFTTIQAIENLLGDEGKPLFGALQNRQHSGLKALMQFAVAQRATCPQVLIHK 1380
VPM+TWSTCAFTTIQAIENLLGDEGKPLFGALQNRQH+GLKALMQFAVAQR TPCQVLI K

Sbjct: 1317 VPMLTWSTCAFTTIQAIENLLGDEGKPLFGALQNRQHNGLKALMQFAVAQRITCPQVLIQK 1376

Query: 1381 HLARLLSVILPNLQSENTPGLLSVDLFHVLVGAVLAFPSIYWDDTVDLQPSPLSSSYNHL 1440
HL RLLSV+LPN++SE+TP LLS+DLFHVVLVGAVLAFPSLYWDD VDLQPS +SSSYNHL

Sbjct: 1377 HLVRLLSVVLPNIKSEDTPELLSIDLFHVLVGAVLAFPSLYWDDPVDLQPSVSSSYNHL 1436

Query: 1441 YLFHLITMAHMLQILLTTDTLSPGPPLAEGEEDSEEARCASAFFVEVSQHTDGLTGCGA 1500
YLFHLITMAHMLQILLT DT G PLA+ +EDSEEA AS+FF E+SQ+T G GC

Sbjct: 1437 YLFHLITMAHMLQILLTVDT----GLPLAQVQEDSEEAHSASSFFABISQYTSIGCDI 1492

Query: 1501 PGWYLWLSLRNGITPYLRCAALLFHYLLGVAPPEELFANSAGEFSALCSYLSLPTNLFL 1560
PGWYLW+SL+NGITPYLRCAAL FHYLLGV PPEEL NSAEGE+SALCSYLSLPTNLFL

Sbjct: 1493 PGWYLWVSLKNGITPYLRCAALFFHYLLGVTPPEELHTNSAEGEYSALCSYLSLPTNLFL 1552

Query: 1561 LFQEYWDTIRPLLQRWCGDPALLKSLKQSAVVRYPRKRNSLIELPEDYSCLLNQASHFR 1620
LFQEYWDT+RPLLQRWC DPALL LKQK+ VVRYPRKRNSLIELP+DYSCLLNQASHFR

Sbjct: 1553 LFQEYWDTVRPLLQRWCADPALLNCLKQKNTVVRYPRKRNSLIELPDDYSCLLNQASHFR 1612

Query: 1621 CPRSADDERKHPVLCLFCGAILCSQNICCQEIVNGEEVGACVFHALHCGAGVCIFLKIRE 1680
CPRSADDERKHPVLCLFCGAILCSQNICCQEIVNGEEVGAC+FHALHCGAGVCIFLKIRE

Sbjct: 1613 CPRSADDERKHPVLCLFCGAILCSQNICCQEIVNGEEVGACIFHALHCGAGVCIFLKIRE 1672

Query: 1681 CRVVLVEGKARGCAYPAPYLDEYGETDPGLKRGNPLHLSRERYRKLHLVWQQHCHIEIEIA 1740
CRVVLVEGKARGCAYPAPYLDEYGETDPGLKRGNPLHLSRERYRKLHLVWQQHCHIEIEIA

Sbjct: 1673 CRVVLVEGKARGCAYPAPYLDEYGETDPGLKRGNPLHLSRERYRKLHLVWQQHCHIEIEIA 1732

Query: 1741 RSQETNQMLFGFNWQLL 1757
RSQETNQMLFGFNWQLL

Sbjct: 1733 RSQETNQMLFGFNWQLL 1749

CPU time: 0.12 user secs. 0.01 sys. secs 0.13 total secs.

Lambda	K	H
0.321	0.136	0.413

Gapped

Lambda	K	H
0.267	0.0410	0.140

Matrix: BLOSUM62

Gap Penalties: Existence: 11, Extension: 1

Number of Sequences: 1

Number of Hits to DB: 21,533

Number of extensions: 13456

Number of successful extensions: 7

Number of sequences better than 10000.0: 1

Number of HSP's better than 10000.0 without gapping: 1

Number of HSP's gapped: 1

Number of HSP's successfully gapped: 1

Length of query: 1757

Length of database: 1,099,805,485

Length adjustment: 147

Effective length of query: 1610

Effective length of database: 1,099,805,338

Effective search space: 1770686594180

Effective search space used: 1770686594180

Neighboring words threshold: 9

X1: 16 (7.4 bits)

X2: 129 (49.7 bits)

X3: 129 (49.7 bits)

S1: 41 (21.9 bits)

S2: 60 (27.7 bits)



My NCBI

[\[Sign In\]](#)
[\[Register\]](#)

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Books

Search for

Limits

Preview/Index

History

Clipboard

Details

Display Show Range: from to ☐ Reverse complemented strand Features: ☐ SNP ☐ CDD ☒☐ 1: [AF061555](#). Reports [Mus musculus ubiq...\[gi:3170886\]](#)[Links](#)

LOCUS AF061555 6395 bp mRNA linear ROD 10-JUL-1998

DEFINITION Mus musculus ubiquitin-protein ligase E3-alpha (Ubr1) mRNA, complete cds.

ACCESSION AF061555

VERSION AF061555.1 GI:3170886

KEYWORDS

SOURCE Mus musculus (house mouse)

ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 6395)

AUTHORS Kwon,Y.T., Reiss,Y., Fried,V.A., Hershko,A., Yoon,J.K., Gonda,D.K., Sangan,P., Copeland,N.G., Jenkins,N.A. and Varshavsky,A.

TITLE The mouse and human genes encoding the recognition component of the N-end rule pathway

JOURNAL Proc. Natl. Acad. Sci. U.S.A. 95 (14), 7898-7903 (1998)

PUBMED 9653112

REFERENCE 2 (bases 1 to 6395)

AUTHORS Kwon,Y.T. and Varshavsky,A.

TITLE Direct Submission

JOURNAL Submitted (24-APR-1998) Division of Biology, 147-75, California Institute of Technology, 1200 E. California Bl., Pasadena, CA 91125, USA

FEATURES Location/Qualifiers

source

1..6395
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/chromosome="2"
/cell_line="MEL-C19"

gene

1..6395
/gene="Ubr1"

5'UTR

1..114
/gene="Ubr1"

CDS

115..5388
/gene="Ubr1"
/note="UBR1p; recognition component of the N-end rule pathway"
/codon_start=1
/product="ubiquitin-protein ligase E3-alpha"
/protein_id="AAC40165.1"
/db_xref="GI:3170887"
/translation="MADEEMDGAERMDVSPEPPLAPQRPASWWDQQVDFYTAFLHHLAQLVPEIYFAEMDPDLEKQEEVSQMSILTPLEWYLFGEPPDICLEKLKHSGAFQLCGKVFKSGETTYSCRDCAIDPTCVLCMDCFQSSVHKHRYKMHTSTGGGFCDCGDEAWKTG"

PFCVDHEPGRAGTTKESLHCPLNEEVIAQARRIFPSVIKYIVEMTIWEEEEKELPPELQ
 IREKNERYCYCVLFNDEHHSYDHVIYSLQRALDCELAEAQLHTTAIDKEGRRRAVKAGVY
 ATCQEAKEDIKSHSENVSQHPLHVEVLHSHVVMMAHQKFALRLGSMNKMYSYSSDFRQI
 FCQACLVEEPGSENPCLISRLMLWDAKLYKGARKILHELIFSSFFMEMEYKKLFAMEF
 VKYYKQLQKEYISDDHERSISITALSVQMLTVPTLARHLIEEQNVISVITETLLEVL
 EYLDNRNKNFNQGYSDQKLGRVYAVICDLKYILISKPIWTERLRAQFLEGFRSFLKI
 LTCMQGMEEIRRVQVGHIEVDPDWEAAIAIQMQLKNILLMFQEWACDEDLVAYKE
 CHKAVMRCSTNFMSSTKTVVQLCGHSLETKSYKVEDLVS IHLPLSRTLGLHVRLSR
 LGAISRLHEFVPPDSFQVEVLVEYPLRCLVLVAQVVAEMWRRNGLSLISQVFFYYQDVK
 CREEMYDKDIIMLQIGASIMDPNKFLLLVLRQYELTDAFNKTISTKDQDLIKQYNTLI
 BEMLQVLIYIVGERYVPGVGNVTREEVIMREITHLLCIEPMPSAIARNLPENENNET
 GLENVINKVATFKKPGVSGHGVYELKDES LKDFNMYFYHYSKTQHSKAEHMOKKRRKQ
 ENKDEALPPPPPEFCPAFSKVNNLLSCDVMYIILRTIFERAVIDTESNLWTEGMLQMA
 FHILALGLLEEKQQLQKAPEEEVAFDFYHKASRLGSSAMNAQNIQMLLERLKGIPQLE
 GQKDMITWILQMFDTVKRLREKSCLVVATTSGLECIKSEEITHDKEKAERKRKAEEAR
 LHRQKIMAQMSALQKNFIETHKLMYDNTSEVTGKEDSIMEEESTSAVSEASRIALGPK
 RGPVATEKEVLTCLCQEEQEVKLENNAMVLSACVQKSTALTQHRGKPVVDHLGETLDP
 LFMDPDLAGHTYTGSCGHVMHACWQKYFEAVQLSSQQRIVDLDFLESGEYLCPLCK
 SLCNTVPIPIPLQPKINSENAEALAQLTLARWIQTVLARISGYNIKHAKEAPAVP
 VLFNQMGDSTFEFHSILSFGVQSSVKYSNSIKEMVILFATTIYRIGLKVPDPDELDP
 VPMMTWSTCAFTIQAIENLLGDEGKPLFGALQNRQHSGLKALMQFAVAQRATCPQVLI
 HKHLARLLSVILPNLQSENTPGLLSVDLFHVLVGAVLAFPSLYWDDTVDLQPSPLSSS
 YNHLYLFLHILITMAHMLQILTTDTLSPGPPLAEGEEDSEEARCASAFFVEVSQHTDG
 LTGCGAPGWYWLWSLRNGITPYLRCAALLFHYLLGVAPPEELFANSAEGEFSALCSYL
 SLPTNLFLLFQEYWDITRPLLQRWCGDPALLKSLKQKSAVVRYPRKRNSLIELPEDYS
 CLLNQASHFRCPRSADDERKHPVLCFLCGAILCSQNICQEIIVNGEEVGACVFHALHC
 GAGVCIFLKIRECRVVLVEGKARGCAYPAPYLDEYGETDPGLKRGNPLHLSRERYRKL
 HLWVQQHCIIIEIARSQETNQMLFGFNWQLL"

3'UTR

5389..6395

/gene="Ubr1"

polyA site

5429..5434

/gene="Ubr1"

ORIGIN

1	cctgactttc	aggggcccgtc	gtaaaagtgt	cgccccctgtc	gcgtcggggcc	ggccacaggt
61	ttccgctagc	tggcgggccgg	gggtcgggaa	ctgcggggcgt	tcgtttccct	taagatggcg
121	gacgaagaga	tggacggcgc	cgagaggatg	gacgtcagcc	cggagccctc	cctggccccg
181	cagcggccgg	catcgtggtg	ggatcagcaa	gttgatttct	atactgcttt	cttacatcat
241	ttggcacaat	tagtgccaga	aatttatatt	gctgagatgg	acccagattt	ggaaaagcaa
301	gaagagagtg	tacagatgtc	aatactcact	cctttggagt	ggtacttatt	tggagaggat
361	ccggatatatt	gcttagagaa	attaaaacac	agtggagcgt	tccagttgtg	tgggaagggt
421	ttcaaaagtg	gagaaacaac	atattccctg	agggattgtg	caattgatcc	aacgtgtgtg
481	ctctgtatgg	actgcttcca	aagtagtggt	cataaaaacc	atcgttacaa	gatgcatact
541	tctactggag	ggggcttctg	tgactgtgga	gacacagaag	cgtggaaaac	tggccctttt
601	tgtgtggatc	acgagcctgg	aagagcaggt	actacaaaag	agagcttaca	ttgccatttg
661	aatgaagagg	tgattgtctc	agccaggaga	atattccctt	cggtgataaa	atacattgta
721	gaaatgacta	tatgggaaga	agaaaaggaa	ttgcctcctg	aactgcagat	aagggaagaaa
781	aatgaacgat	actattgtgt	ccttttcaac	gatgagcacc	attcgtagta	tcatgtgatc
841	tacagtctgc	agagagctct	agattgagag	cttgagagag	cacagctgca	cacgactgcc
901	atcgacaaaag	agggtcgccc	ggctgtcaaa	gcaggtgtgt	atgccacttg	ccaggaagca
961	aaggaggata	taaagagtca	ctcagagaa	gtctctcagc	acccctcca	tgtggaagtg
1021	ctgactccg	tgggtatggc	tcaccagaaa	ttcgctctgc	gccttggctc	ctggatgaac
1081	aaaattatga	gctattcaag	tgactttaga	cagatatattt	gccaggcctg	cctcgtagaa
1141	gaacctggct	ctgaaaatcc	ctgtcttata	agcagactaa	tgctttggga	tgcaaaactt
1201	tataaagggtg	cccgttaagat	ccttcattga	ttgatcttta	gtagtttttt	tatggagatg
1261	gaatacaaaa	aactctttgc	tatggaattt	gtgaagtatt	ataaacaact	gcagaaagag
1321	tacatcagcg	acgaccacga	gagaagcatc	tccataaccg	ccctgtccgt	gcagatgctc
1381	accgtcccga	ccttgggccc	gcattctatt	gaagagcaga	atgttatatt	tgctattact
1441	gaaacgctgc	tagaagtttt	acctgaatac	ttggacagga	acaataaatt	caacttccag
1501	ggttatagcc	aggacaaaact	gggaagagtc	tacgcagtta	tatgtgacct	aaagtatatc
1561	ctgattagca	agcctgtcat	atggacagaa	cgattaagag	cgcagttcct	ggaaggtttc

1621 cgggtcttttc tgaagattct tacctgtatg caggggaatgg aagaaatcag aagacaagtt
1681 ggacaacaca ttgaagtggg ccctgactgg gaggctgcca tcgctataca gatgcaacta
1741 aagaatatatt tgctcatgtt ccaagagtgg tgtgcttggt atgaagatct cttactgggtg
1801 gcttataaaag aatgtcacaa agctgtaatg aggtgcagta caaatttcat gtccagtacc
1861 aagacagtag tgcaattgtg cggcatagt ctggaaacca aatcctacaa agtgtctgag
1921 gaccttgtaa gcatacacct gccactctct agaacacttg ctggtcttca tgtacgttta
1981 agcagactag gtgctatttc aagactgcat gaatttgctg cttttgacag ctttcaagta
2041 gaggtcctgg tggagtaccc gctgcgctgc ctggtcctgg tggctcaggt tgttgctgag
2101 atgtggcgaa gaaacgggct ctactcatc agccagggtt tctattatca agatgttaaa
2161 tgcagggagg aaatgtacga taaagatac atcatgcttc agattggagc atctataatg
2221 gatcccaaca agttcttggt actggtactt cagagatatg aacttactga tgcttttaac
2281 aagaccatat ccacaaaaga ccaggatttg attaaacagt ataatacatt aatagaagaa
2341 atgcttcagg tcctcatcta tattgtggga gaacgttatg tacctggagt gggaaatgtt
2401 accagagagg aggttataat gagagagatt actcacttac tttgcattga gcccatgcc
2461 cacagtgcc tgcgcaaaa cctacctgag aacgaaaata atgaaactgg cttagagaat
2521 gtcataaaaca aagtggccac atttaagaaa ccagggtgtg cgggccatgg agtttatgaa
2581 ttgaaagatg aatcactgaa agacttcaat atgtactttt accattattc taaaacacag
2641 catagcaagg ctgaacatat gcagaagaaa aggagaaaac aagaaaataa agatgaagca
2701 ttgccgccgc cacctcctcc agagtctgct cctgctttca gcaaagtagt caacctgtc
2761 agctgtgatg ttatgatata catctcagg accatctttg agcgggcagt ggacacggag
2821 tctaactctgt ggacagaagg gatgctgcag atggcgctcc atatattggc actgggcttg
2881 ctggaagaga agcagcagct tcagaaagct cctgaagagg aagtggcttt tgacttttac
2941 cataaagctt caagattggg aagttcagcc atgaatgctc agaatacata aatgctcttg
3001 gaaagactca aaggaatccc ccaattagaa ggccagaagg acatgataac atggatactc
3061 cagatgtttg acacagtga gcgattaaga gaaaaatctt gtttagttgt ggcaaccact
3121 tcaggactgg agtgcattaa gagtgaggag attactcatg ataaagaaaa ggcagaacgg
3181 aagagaaaaa ctgaggccgc taggcttcat cgccagaaga tcatggcca gatgtctgcc
3241 ttacagaaaa acttcattga aaccacaaa ctcatgtatg ataatacgtc agaagtaaca
3301 gggaagggaag actccattat ggaggaagag agcacctcag cagtcagtga ggcctctaga
3361 attgctctgg gccctaaacg gggcccggtt gttaccgaaa aggaggtgct gacgtgcac
3421 ctctgccaaag aagaacaaga ggtaaaacta gaaaataatg ccatggtatt gtcagcatgt
3481 gtgcagaaat ccaccgccct aaccagcac agaggggaagc ctgtggacca cttaggggaa
3541 aactggacc ctcttttcat ggatccagac ttggcacatg gaacttatac aggaagctgt
3601 ggtcatgtaa tgcattgcag gtgctggcag aagtattttg aagctgtgca gctgagctcg
3661 cagcagcgca ttcacgtaga cctgtttgac ctggagagcg gcgagtacct atgcccgtc
3721 tgcaagtctc tctgcaacac tgtcatcccc atcatccctt tgcagccgca gaagatcaac
3781 agtgagaatg cggaggctct tgtcaactt ttgaccttg cccgggtgat acagactgtc
3841 cttgccagaa tatcggttga taatataaag catgctaaag gagaagcccc agcagttcct
3901 gtcttggtta atcaaggaat gggggattca acttttgagt ttcattccat cctgagtttt
3961 ggagttcagt cttcggtgaa atattcaaat agtatcaagg aaatgggtcat tctcttcgcc
4021 acaacaattt acagaattgg cctgaaagt cctcctgatg aactagacc acgagtgccc
4081 atgatgacct ggagcacgtg tgcgttaccc atccaggcaa tcgaaaacct gttgggagat
4141 gaaggaaaac ctctatttgg agcacttcaa aatagacagc atagcggctt gaaggcgcta
4201 atgcagtttg cagttgcaca gagggtacc tgccctcagg tcttgataca caaacatctg
4261 gtcgggtcc tgtcagttat tcttccaaac ctgcaatcag aaaatacacc aggccttctg
4321 tctgtggatc tcttccatgt tctggctggc gcagtcttag cgttcccatc cttgtattgg
4381 gatgacaccg tggatctgca gccgtcgcca cttagttctt catataacca cctctatctc
4441 ttccatctga tcaccatggc gcacatgctt cagatactcc ttacaacaga tacagatctg
4501 tctccagggc cgccgcttgc tgagggtgaa gaggatagtg aggaggctcg ctgtgcactc
4561 gctttctttg tggaagtgtc gcagcacaca gacggcctca ctgggtgagg tgctcccggc
4621 tggtagctgt gggtctccct gaggaacggc atcaccctt acctccgtg tgctgcactg
4681 cttttccact atttacttgg agtagctccg cctgaagaac tgtttgccaa ttctgctgaa
4741 ggagaattca gtgcactctg tagctatcta tctttacca caaatttggt cctgcttttc
4801 caggaatatt gggataccat aaggccctta ctacagaggt ggtgtggaga tctgcctta
4861 ctcaagtctt tgaagcagaa aagtgtgtg gtcagggtacc ctagaaaaag aaatagtttg
4921 atagagcttc ctgaggacta cagctgtctt ctaaatacagg cttctcactt taggtgtcca
4981 cgtgtctgag atgatgagcg aaagcatcct gtccctctgtc tttctctgtg ggccatcctg
5041 tgttctcaga acatctgttg ccaagaaata gtgaatgggg aagaggttgg agcgtgcgtt
5101 tttcatgcgc ttcatgttgg tgctggagtc tgcattttcc taaaaatccg agaatgcagg
5161 gtggtcctgg tggaaggaaa agccagaggc tgtgcctacc cagccctta cttggatgaa

5221 tatggagaaa cagacccagg gctaaagaga ggaaaccac ttcatttata tcgggagcgg
5281 tatcggaagc tgcatttggc ctggcaacag cactgcatta tagaagagat tgctcggagc
5341 caggagacta atcagatgct atttggattt aactggcagt tactctgagc ttcagttctg
5401 cctcaagaca atcatgagt acatcaataa taaagactga tctaaaattc tagagaactt
5461 tctgaggacg ggggaagtat tggagggtct tttgatccat gtccagattc acacacatta
5521 ataaaatatt ccttaatgga atattgcttt caattatcaa acataagctt caagggaata
5581 acaagacata gattaatggt ttatgttcta gaacactaaa gaaatgcttg ttcattccag
5641 tgtctatttc tgctaataat tccagaaaac tcctttccct tcataactgt cctagttcat
5701 ttcataatcac ccacctgggt aatgagggtc cattaagcat ttgtggacat ttctccatct
5761 ggctaacatc tctgcacctt tgtatttggc gtttctcgag tgtagtttag cttggggttag
5821 atctctgaaa agatgctgat cacctgtgat ggtctaaaga ggaattgcac aactatgcag
5881 tttctttcaa ttaaaaattt caaaacatgt aaacatcttt cttctttaag gaaatatcct
5941 tattgtacca cctacggctt cagtcagaaa cagatctaaa tctctctatg gagagtgcta
6001 gctgtgctag tctggaaagc atccttccag tgtagacctc aagtagattc aggagaatgt
6061 gctcattacg cattccttat acaaaatcct gttatcctca cctgattcca gggagctctg
6121 tggagtcaca agttctccat cagttacatt tcttaaggca gatttctgca gtaagatctc
6181 gtctcttggg gccccatcct attgtctctc agaaaactct tgttttgaag caaactcttt
6241 gtagaatggg aatcagaaaa ttgccccagt gaatggctat aagagatgaa attagaacac
6301 tgtattttaag ccagttctgc aaccttctat ggcttgtaag aaacaggctc ttgatttgat
6361 gtctaggtga aacctttcat aaacgactgt ttatg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Dec 8 2005 13:13:13

BEST AVAILABLE COPY

FIG. 2

Tth Expression Profile of huE3 α -II in Human Tissues




FIG. 3

Tth Expression Profile of huE3 α -I in Human Tissues




Figure 4
Ubiquitination of Endogenous Proteins




Figure 5
Transfection of Human E3a-I or E3a-II cDNA Stimulates
Ubiquitin Conjugation in Cultured Muscle Cell Lines




Figure 6
¹²⁵I-Ubiquitin Conjugation to Muscle Proteins and Its Sensitivity to E3α Inhibitor
in Skeletal Muscle Extracts




Figure 7
Rates of Ubiquitination of N-end Rule Substrate
 α -Lactalbumin in Skeletal Muscle Extracts




Figure 8

**Northern blot analysis of E3 α -I & E3 α -II expression
in gastrocnemius muscles in YAH-130 experimental cachexia model**





Figure 9

Northern blot analysis of E3 α -I and E3 α -II expression in
gastrocnemius muscle and cardiac muscle
in C26 experimental cachexia model



e.




Figure 11
IL-6 Elicits Accelerated Ubiquitination in C2C12 Myotube Cultures





Figure 12
TNF α Elicits Accelerated Ubiquitination in C2C12 Myotube Cultures



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.